|
|
Post by lennymnkd on Jun 11, 2023 7:22:17 GMT -5
|
|
|
|
Post by liane on Jun 11, 2023 9:08:56 GMT -5
06/11/23
PDF Version
DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for increased production capacity of Tyvaso DPI®.
Through MannKind’s partnership with United Therapeutics the current expansion project represents a $60 million investment. Construction is ongoing to build out new manufacturing space designed to expand production in anticipation of the continued growth of Tyvaso DPI. In the past two years, MannKind has experienced more than a 250% increase in its Connecticut workforce across manufacturing, R&D and support functions.
DATE/TIMES: MONDAY, JUNE 12, 2023
10:00 a.m. – 11:00 a.m.
LOCATION: MannKind
40 Taylor Street (Danbury, CT)
VISUALS/SOUND: - Governor Lamont tours facility with MannKind CEO Dr. Michael Castagna and COO Lauren Sabella
- Construction underway on “clean rooms” and spray dry equipment in new manufacturing space
- Demonstration of MannKind’s innovative Technosphere® particle and device technologies
- Production personnel producing the particle technology used as part of our inhaled insulin (Afrezza®) as well as Tyvaso DPI
MANNKIND: MannKind Corporation focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
CONTACT: MannKind Corporate Communications
Christie Iacangelo (on-site)
(818) 292-3500 (mobile)
ciacangelo@mnkd.com
|
|
|
|
Post by Clement on Jun 11, 2023 9:16:04 GMT -5
1. The governor visits. That's good PR.
2. "The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for increased production capacity of Tyvaso DPI®."
3. "the current expansion project represents a $60 million investment"
4. "In the past two years, MannKind has experienced more than a 250% increase in its Connecticut workforce across manufacturing, R&D and support functions."
|
|
|
|
Post by mango on Jun 12, 2023 11:08:02 GMT -5
Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing MilestoneDANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for increased production capacity of Tyvaso DPI®.
Through MannKind’s partnership with United Therapeutics the current expansion project represents a $60 million investment. Construction is ongoing to build out new manufacturing space designed to expand production in anticipation of the continued growth of Tyvaso DPI. In the past two years, MannKind has experienced more than a 250% increase in its Connecticut workforce across manufacturing, R&D and support functions.Points of interest in this positive PR, aside from the governor touring the plant: • United Therapeutics has made a $60 million dollar investment into the expansion of MannKind’s manufacturing facility to accommodate for the drastic increase in future demand of Tyvaso DPI. • MannKind has experienced a 250% increase MannKind has a very cool tour planned today for the Governor: VISUALS/SOUND: - Governor Lamont tours facility with MannKind CEO Dr. Michael Castagna and COO Lauren Sabella - Construction underway on “clean rooms” and spray dry equipment in new manufacturing space - Demonstration of MannKind’s innovative Technosphere® particle and device technologies - Production personnel producing the particle technology used as part of our inhaled insulin (Afrezza®) as well as Tyvaso DPI investors.mannkindcorp.com/news-releases/news-release-details/governor-ned-lamont-tour-mannkind-june-12-it-reaches
|
|
|
|
Post by prcgorman2 on Jun 12, 2023 13:27:01 GMT -5
|
|
|
|
Post by jkendra on Jun 12, 2023 14:23:18 GMT -5
|
|
|
|
Post by harryx1 on Jun 12, 2023 14:29:19 GMT -5
|
|
|
|
Post by runner on Jun 12, 2023 14:49:11 GMT -5
1. The governor visits. That's good PR. 2. "The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for increased production capacity of Tyvaso DPI®."3. "the current expansion project represents a $60 million investment" 4. "In the past two years, MannKind has experienced more than a 250% increase in its Connecticut workforce across manufacturing, R&D and support functions." Anyone know how many staff they have there as of now? When I toured the facility at the 2015 shareholders meeting they said they were approximately 400 staff. |
|
|
|
Post by jkendra on Jun 12, 2023 14:55:59 GMT -5
Gov. Ned Lamont said he viewed the manufacturer as "one of the best-kept secrets in Connecticut" after taking a tour of the company's production and research buildings Monday. "What they're doing with the inhaler, I think, is the next generation of drug delivery," Lamont said Monday. "These guys are at the forefront of it, and look at what their growth has been in the last few years." From $12 million in the first three months of 2022, MannKind more than tripled revenue to $40.6 million through March this year. The company narrowed its first-quarter loss to below $10 million from $25 million a year ago. On Monday, Castagna declined to project when he expects MannKind to become profitable. Should physicians see Tyvaso DPI as a superior alternative to existing treatments, that could vault MannKind into a sustained expansion. Last month, Castagna predicted that for every 10,000 patients who are prescribed Tyvaso DPI, it would result in $200 million in annual revenue for MannKind. United Therapeutics' confidence in the drug is such that it is currently building its own plant to produce Tyvaso DPI, with Castagna saying the decision makes sense as a hedge against any disruption to production in Danbury. That scenario hit a Genzyme plant nearly 15 years ago in Boston, interrupting production of two drugs with no fallback manufacturing option in place at the time. |
|
